Hypogonadism (Acute Presentation)MANAGEMENT

ENDOCRINE AND METABOLIC PRESENTATIONS · 12 SECTIONS

⚲

635 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

Acute Porphyria Adrenal crisis Adrenal Insufficiency (Addisonian Crisis)Dehydration Diabetes Insipidus Diabetic Ketoacidosis (DKA)Euglycemic DKA (SGLT2 inhibitor)Galactosemia GLP-1 receptor agonist complications (retained gastric contents, aspiration risk)Homocystinuria Hypercalcemia Hyperkalemia Hypermagnesemia Hypernatremia Hyperosmolar Hyperglycemic State (HHS)Hypertensive emergency Hypertensive urgency Hypocalcemia Hypoglycemia Hypogonadism (Acute Presentation)Hypokalemia Hypomagnesemia Hyponatremia Hypoparathyroidism (Tetany)Insulin pump failure Maple Syrup Urine Disease (Crisis)Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCAD)Metabolic Acidosis Metabolic Alkalosis Myasthenia gravis crisis Myxedema coma Pellagra Pheochromocytoma (Crisis)Pituitary Apoplexy Pompe Disease (GSD II)Respiratory Acidosis Respiratory Alkalosis Scurvy SIADH Starvation Ketosis Tarui Disease (GSD VII)Thyroid storm Tyrosinemia Vitamin D Deficiency (Severe-Rickets)Von Gierke Disease (GSD I)

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp47

Emergent presentations

›Life-threatening acute syndromes

›Pituitary apoplexy

›Sudden severe headache + visual loss + ophthalmoplegia

›May mimic subarachnoid hemorrhage

›Concurrent ACTH deficiency can cause hemodynamic collapse

›Adrenal crisis from panhypopituitarism

›Hypotension refractory to IV fluids

›Hyponatremia + hypoglycemia + hypothermia

›Requires immediate IV hydrocortisone

›Testicular torsion as primary hypogonadism cause

›Acute scrotal pain, surgical emergency

›Viable salvage rate >90% if exploration within 6 hours

Immediate stabilization

›ABC priorities

›Airway and hemodynamics

›IV access x2 for unstable patients

›Continuous cardiac monitoring

›Pulse oximetry

›Pituitary apoplexy resuscitation

›IV hydrocortisone 100-200 mg bolus immediately

›Then 50-100 mg IV q6h

›IV fluid resuscitation for hypotension

›Adrenal crisis protocol

›IV hydrocortisone 100 mg bolus

›0.9% NaCl 1 L bolus; repeat as needed

›50% dextrose for hypoglycemia

›Target SBP >90 mmHg, glucose >3.9 mmol/l

02History/hx77

Symptom onset and timeline

›Onset characterization

›Sudden severe headache with visual changes

›Suggests pituitary apoplexy until proven otherwise

›Thunderclap onset peaks within seconds to minutes

›Gradual onset over weeks to months

›Decreased libido, fatigue, depressed mood

›Erectile dysfunction, loss of morning erections

›Acute scrotal pain

›Testicular torsion as primary hypogonadism cause

Sexual and reproductive symptoms

›Highest-specificity symptoms for hypogonadism

›Decreased libido

›Most specific symptom for low testosterone

›Strongest predictor of treatment response

›Erectile dysfunction

›Loss of morning (spontaneous) erections

›Decreased sexual activity frequency

›Reproductive symptoms

›Infertility, decreased ejaculate volume

›Small or soft testes

Constitutional and nonspecific symptoms

›Systemic symptom complex

›Fatigue and low energy

›Reduced physical performance and exercise capacity

›Anemia contributing to fatigue

›Mood and cognitive symptoms

›Depressed mood, irritability

›Poor concentration, cognitive decline

›Vasomotor symptoms

›Hot flashes with abrupt testosterone withdrawal

›Post-orchiectomy or GnRH agonist-induced

Alarm features

›Cannot-miss red flags

›Neurologic alarm features

›Bitemporal hemianopia or cranial nerve palsy

›Altered mental status, meningismus

›Visual acuity loss

›Hemodynamic alarm features

›Hypotension or syncope

›Persistent nausea/vomiting with dizziness

Medication and substance history

›Causative medications

›Opioids — most common drug-induced cause

›Prevalence of hypogonadism >50% in chronic opioid users

›Methadone, morphine most potent HPG suppressors

›Duration >3 months significantly increases risk

›Anabolic-androgenic steroid use and withdrawal

›Withdrawal causes profound hypogonadotropic hypogonadism

›Suppressed LH/FSH with low testosterone

›Glucocorticoids

›Prednisone >=15 mg/day can suppress testosterone within 3 days

›Other causative agents

›GnRH agonists/antagonists (prostate cancer therapy)

›Ketoconazole, spironolactone

›Immune checkpoint inhibitors (hypophysitis)

›Anticonvulsants, barbiturates

Risk factors

›Predisposing conditions

›Obesity (BMI >30)

›Most common cause of functional hypogonadism in middle-aged men

›Weight loss can increase endogenous testosterone

›Type 2 diabetes and metabolic syndrome

›Chronic opioid use >3 months

›Prevalence of hypogonadism 50-85%

›Prior pituitary adenoma or surgery

›Chemotherapy or radiation to testes or brain

›Head trauma or TBI

›HIV infection, hemochromatosis

›Chronic kidney disease, liver disease, COPD

Family and social history

›Familial and inherited risk

›Family history of anosmia, delayed puberty, midline defects

›Suggests Kallmann syndrome (ANOS1 mutation, X-linked)

›Family history of infertility or learning difficulties

›Klinefelter syndrome 47,XXY

›Hereditary hemochromatosis — iron overload causing secondary hypogonadism

Past medical history

›Relevant prior diagnoses

›Prior testicular surgery, trauma, torsion, or cryptorchidism

›Mumps orchitis

›Known pituitary adenoma

›Prior fragility fractures or osteoporosis

›Sleep apnea (risk factor and contraindication to TRT)

›Prior thromboembolism (contraindication to TRT)

03Physical Exam/exam58

Vital signs

›Hemodynamic assessment

›Blood pressure

›Hypotension suggests adrenal crisis or pituitary apoplexy

›SBP <90 mmHg triggers immediate resuscitation

›Heart rate

›Bradycardia may indicate concurrent hypothyroidism

›Tachycardia with fever suggests pituitary apoplexy

›Temperature

›Hypothermia in panhypopituitarism

›Blood glucose at bedside

›Hypoglycemia in pituitary-adrenal failure

Neurologic and ophthalmologic exam

›Cranial nerve and visual assessment

›Visual fields by confrontation

›Bitemporal hemianopia suggests chiasmal compression

›Unilateral field defect suggests asymmetric mass

›Extraocular movements

›CN III palsy: ptosis, pupil dilation, down-and-out gaze

›CN IV/VI palsy: diplopia patterns

›Pupillary reactivity

›Afferent pupillary defect in optic nerve compression

›Anosmia testing

›Absent sense of smell suggests Kallmann syndrome

›Mental status

›GCS, orientation, memory

Genitourinary exam

›Testicular assessment

04Differential Diagnosis/ddx47

Life-threatening diagnoses

›Cannot-miss emergencies

›Pituitary apoplexy

›ICD-10: E23.6 (hypopituitarism), I60.8 (pituitary hemorrhage)

›Sudden headache + visual loss + ophthalmoplegia

›Hemorrhage or infarction of pituitary adenoma

›Adrenal crisis with panhypopituitarism

›ICD-10: E27.2

›Hypotension, hyponatremia, hypoglycemia

›ACTH deficiency from pituitary failure

›Testicular torsion

›ICD-10: N44.0

›Acute scrotal pain, absent cremasteric reflex

›Surgical emergency within 6 hours

Secondary hypogonadism causes

›Pituitary and hypothalamic pathology

›Prolactinoma

›ICD-10: D35.2

›Galactorrhea, visual field deficits, low LH/FSH

›Elevated prolactin suppresses GnRH

›Non-functioning pituitary macroadenoma

›Mass effect causing gonadotropin deficiency

›Bitemporal hemianopia without hormone excess

›Congenital hypogonadotropic hypogonadism / Kallmann syndrome

›ICD-10: E23.0

›Anosmia, absent puberty, low LH/FSH

Drug-induced and functional causes

›Reversible causes

05Laboratory Tests/lt58

Testosterone measurement

›Total testosterone — primary diagnostic test

›Fasting morning specimen (7-10 AM) required

›Testosterone drops postprandially — fed state causes false low

›Draw after adequate sleep

›Confirmed on >=2 separate occasions

›~30% of initially low values normalize on repeat testing

›Do NOT diagnose during acute illness — transient suppression

›Threshold for biochemical hypogonadism

›Total testosterone <10.4 nmol/l (<300 ng/dL)

›Endocrine Society guideline threshold

Hormone axis evaluation

›LH and FSH — classification test

›Primary hypogonadism pattern

›LH and FSH elevated (hypergonadotropic)

›Testicular failure: Klinefelter, orchitis, torsion sequelae

›Secondary hypogonadism pattern

›LH and FSH low or inappropriately normal (hypogonadotropic)

›Pituitary or hypothalamic cause

›Free testosterone

›Indicated when total testosterone borderline low

›Obesity, liver disease, aging alter SHBG

›Calculated or equilibrium dialysis method preferred

›SHBG

›Elevated SHBG (aging) raises total while free testosterone is low

›Decreased SHBG (obesity, diabetes) lowers total with normal free

›Prolactin

›Elevated in prolactinoma

06Diagnostic Tests/dt65

Scoring Systems

›Clinical diagnosis scoring tools

›ADAM questionnaire (Androgen Deficiency in Aging Males)

›10-item validated screening tool

›Sensitivity 88%, specificity 60%

›Positive if question 1 or 7 positive, or >=3 other questions positive

›AMS scale (Aging Males' Symptoms)

›17-item self-reported symptom scale

›Score >=37 suggests significant androgen deficiency

›Used to track symptom response to therapy

›Pituitary Apoplexy Score

›Grades 0-10 based on visual acuity, visual fields, consciousness

›Score >=4 predicts need for surgical decompression

›DEXA bone mineral density

›T-score >= -2.5 = osteoporosis; -1 to -2.5 = osteopenia

›Baseline recommended in all confirmed hypogonadal men

MRI

›MRI indications and protocols

›MRI of the sella turcica (gold standard for pituitary pathology)

›Indicated in all confirmed secondary hypogonadism

›Protocol: thin-section coronal T1 pre and post gadolinium

›3 mm slices through sella

›Indications for MRI sella

›Prolactin >100 mcg/l

›Any visual field defect or cranial nerve palsy

›Suspected pituitary apoplexy (after CT if CT negative)

›Panhypopituitarism or multiple pituitary hormone deficiencies

›LH/FSH low without clear reversible cause

07Disposition/dispo35

Emergent admission

›Immediate hospital admission criteria

›Pituitary apoplexy with any of the following

›Visual deterioration or new cranial nerve palsy

›Altered consciousness or GCS <15

›Hemodynamic instability

›Requires neurosurgery and ICU-level monitoring

›Adrenal crisis requiring IV hydrocortisone

›Cannot be managed as outpatient

›IV access, monitoring, fluid resuscitation required

›Testicular torsion

›Surgical admission for emergent exploration

›Within 6 hours from symptom onset for best salvage

Observation and monitored care

›Intermediate-level disposition

›Pituitary apoplexy with stable visual fields and mild symptoms

›Conservative management with close monitoring acceptable

›Serial visual field assessments every 24-48 hours

›Repeat MRI at 24-72 hours

›Suspected panhypopituitarism awaiting full workup

›Empiric hydrocortisone if cortisol pending and clinically unstable

Safe discharge criteria

›Outpatient pathway requirements

›No alarm features (stable hemodynamics, intact vision, no AMS)

›Suspected functional or chronic hypogonadism

›Normal basic metabolic panel and glucose

›Confirmed outpatient follow-up arranged

›Endocrinology referral for confirmed hypogonadism

08Treatment/t79

Emergent interventions

›Pituitary apoplexy management

›Glucocorticoid replacement — immediate

›IV hydrocortisone 100-200 mg bolus

›Then 50-100 mg IV q6h

›Continue until stable and able to transition to oral

›Indication: all suspected pituitary apoplexy with hemodynamic compromise

›Class I recommendation from Endocrine Society

›Hemodynamic support

›0.9% NaCl IV: 1-2 L initial bolus for hypotension

›Vasopressors (norepinephrine) if refractory to fluids + hydrocortisone

›Dextrose 50% IV for hypoglycemia

›Surgical decompression

›Trans-sphenoidal surgery for visual deterioration or altered consciousness

›Optimal timing: within 7 days of onset improves visual outcomes

›Pituitary Apoplexy Score >=4 predicts surgical need

Adrenal crisis treatment

›Acute adrenal insufficiency protocol

›IV hydrocortisone 100 mg bolus

›Then 200 mg/24h by continuous infusion or 50 mg q6h

›Taper to oral once stable (hydrocortisone 20-30 mg/day in divided doses)

›IV fluid resuscitation

›0.9% NaCl; avoid hypotonic fluids

›Correct hyponatremia slowly: max 8-10 mmol/l per 24 hours

›Glucose management

›50% dextrose 50 mL IV bolus for glucose <3 mmol/l

›Continuous dextrose infusion if recurrent hypoglycemia

Testosterone replacement therapy (TRT) — outpatient initiation

›TRT formulations and dosing

›Transdermal gel (preferred for older men or initial therapy)

›Testosterone 1.62% gel: starting dose 40.5 mg/day to shoulders/upper arms

›Titrate at 14 and 28 days based on morning testosterone levels

›Target mid-normal range: 15-20 nmol/l (450-600 ng/dL)

›Testosterone 1% gel: 5 g/day equivalent starting dose

›Injectable testosterone

›Testosterone cypionate: 100-200 mg IM every 1-2 weeks

›Peak-trough variation higher than transdermal

›Testosterone undecanoate: 1000 mg IM loading, then 1000 mg at 6 weeks, then q12 weeks

›More stable levels, less frequent dosing

›Transdermal patch

›4 mg/day nocturnal application to non-scrotal skin

›Higher skin irritation rate than gel

TRT contraindications

›Absolute contraindications

›Men planning fertility in near term

›TRT suppresses spermatogenesis — not contraceptive

›Use gonadotropin therapy (hCG +/- FSH) or clomiphene citrate instead

›Known or suspected prostate cancer

›Known or suspected breast cancer in men

›Hematocrit >50% — polycythemia risk

›Stop TRT if hematocrit exceeds 54%

›Untreated severe OSA

›Uncontrolled heart failure

›Recent MI or stroke within 6 months

›Active thrombophilia or high VTE risk

Fertility-preserving alternatives

›Options for secondary hypogonadism with fertility desire

›Human chorionic gonadotropin (hCG)

›1500-3000 IU SC 3x/week to stimulate testicular testosterone

›Maintains intratesticular testosterone and spermatogenesis

›Clomiphene citrate (off-label)

›25-50 mg orally every other day

›Blocks estrogen receptor at hypothalamus; increases GnRH pulsatility

›Increases LH/FSH and endogenous testosterone

›Recombinant FSH

›Added when hCG alone insufficient for spermatogenesis induction

TRT monitoring protocol

›Ongoing monitoring requirements

›Testosterone levels, hematocrit, symptom assessment

›At 3-6 months after initiation, then annually

›Target mid-normal testosterone range

›PSA and DRE at baseline and 3-12 months post-initiation (men >=40)

›PSA rise >1.4 mcg/l above baseline: urology referral

›Hematocrit monitoring

›Stop TRT if hematocrit >54%; evaluate for hypoxia/OSA

›Bone mineral density (DEXA)

›After 1-2 years if osteoporosis present at baseline

Reversal of functional hypogonadism

›Non-pharmacologic first-line for reversible causes

›Obesity-related functional hypogonadism

›Weight loss 5-10% increases testosterone by 2-4 nmol/l

›Target BMI <25; bariatric surgery in severe obesity

›Opioid-induced hypogonadism

›Opioid dose reduction or rotation

›Buprenorphine less suppressive than full mu-agonists

›TRT considered if opioid cannot be discontinued

09Special Populations/sp53

Pregnancy

›Hypogonadism in women — endocrine considerations

›Female hypogonadism (premature ovarian insufficiency)

›Defined as loss of ovarian function before age 40

›FSH >25 IU/l on >=2 measurements 4 weeks apart

›Presents with oligo/amenorrhea, hot flashes, infertility

›Hormone replacement in premenopausal women

›Estrogen-progestin replacement to protect bone and cardiovascular health

›Combined OCP acceptable if no contraindication

›Continue until natural age of menopause (51 years)

›Pregnancy implications

›Testosterone and most anabolic agents absolutely contraindicated in pregnancy

›GnRH agonists contraindicated — suppress fetal HPG axis

›Pituitary apoplexy in pregnancy: Sheehan syndrome

›Postpartum pituitary infarction from hemorrhage/shock

›Failure of lactation, amenorrhea, fatigue post-delivery

Geriatric

›Testosterone in older men (age >=65)

›Age-related testosterone decline

›Testosterone declines 1-2% per year after age 30

›Late-onset hypogonadism: testosterone <10.4 nmol/l with symptoms

›SHBG rises with aging, reducing free testosterone disproportionately

›TRT benefits in older men

›Improved sexual function, libido, bone density

›Modest improvements in muscle mass and physical function

›TRAVERSE trial (2023): no increased major cardiovascular events vs placebo

›TRT risks in older men

›Polycythemia: monitor hematocrit at 3-6 months

10Background/b64

Epidemiology

›Prevalence and incidence data

›Male hypogonadism prevalence

›Biochemical hypogonadism (total testosterone <10.4 nmol/l): 2-6% of men overall

›In men aged 40-79: prevalence 6% with biochemical + symptomatic criteria

›Functional hypogonadism (obesity, opioids): up to 50% in selected populations

›Opioid-induced hypogonadism

›Prevalence 50-85% in chronic opioid users (>3 months)

›Methadone highest risk among opioids

›Recovery possible after opioid cessation in some patients

›Pituitary apoplexy incidence

›6.2 cases per million per year

›Occurs in 2-7% of patients with known pituitary adenoma

›Peak incidence in 5th-6th decade

›Klinefelter syndrome

›1 in 500-1000 male births; most common sex chromosome aneuploidy

›>50% remain undiagnosed during lifetime

›Testicular torsion

›Annual incidence 1 in 4000 males under age 25

›Bimodal distribution: neonatal and peripubertal

›Bilateral infertility risk if contralateral torsion unrecognized

Pathophysiology

›HPG axis physiology and failure mechanisms

›Normal HPG axis

›Hypothalamic GnRH (pulsatile) stimulates pituitary LH and FSH

›LH stimulates Leydig cell testosterone production

›FSH stimulates Sertoli cells for spermatogenesis

›Testosterone and inhibin B provide negative feedback

›Primary hypogonadism (hypergonadotropic)

›Testicular failure: Leydig cell destruction or dysfunction

›LH/FSH elevated (lost negative feedback)

›Causes: Klinefelter, mumps orchitis, chemotherapy, torsion, radiation

›Secondary hypogonadism (hypogonadotropic)

›Pituitary or hypothalamic failure: reduced LH/FSH

›Low testosterone with low or inappropriately normal LH/FSH

›Causes: pituitary adenoma, apoplexy, opioids, GnRH deficiency

›Functional hypogonadism

›Reversible HPG suppression without structural pathology

›Obesity: excess aromatase converts testosterone to estradiol

›Opioids: mu-receptor agonism at hypothalamus suppresses GnRH pulsatility

›Pituitary apoplexy mechanism

›Rapid expansion of adenoma by hemorrhage or infarction

›Compresses normal pituitary — acute pan-hypopituitarism

›Cavernous sinus involvement: CN III, IV, VI palsies

›Chiasmal compression: bitemporal hemianopia

Therapeutic Considerations

›TRT evidence base

›Endocrine Society Clinical Practice Guideline 2018 (Bhasin et al.)

›TRT recommended for men with consistently low testosterone + symptoms

›Two morning testosterone measurements required before initiating TRT

›Class I recommendation for sexual symptom improvement

›TRAVERSE trial (2023, NEJM)

›N=5246 men aged 45-80 with hypogonadism and elevated CV risk

›Testosterone non-inferior to placebo for MACE at 33 months

›Increased atrial fibrillation, pulmonary embolism, and acute kidney injury risk

›Cochrane review 2024 (Lee et al.)

›TRT improves sexual desire and erectile function vs placebo

›Strongest benefit in men with baseline testosterone <8 nmol/l

›European Urology 2025 guidelines (Boeri et al.)

›Structured monitoring protocol mandatory with TRT initiation

›PSA + DRE mandatory at 3-6 months and annually

›Opioid-induced hypogonadism evidence

›Fountas et al. Lancet Diabetes Endocrinol 2020: opioid dose-dependent HPG suppression

›Recovery of HPG axis after cessation reported in 20-year cohort study

›Pituitary apoplexy management

›Biagetti et al. Eur J Endocrinol 2026: updated management recommendations

›Hydrocortisone + surgical decompression for moderate-severe cases

11Patient Discharge Instructions/pdi25

copy discharge instructions

›Diagnosis and return instructions

›You have been evaluated for hypogonadism (low testosterone)

›This condition occurs when the body does not produce enough testosterone

›You need follow-up blood tests to confirm the diagnosis

›Return to the emergency department immediately if you develop

›Sudden severe headache, especially with visual changes or double vision

›Dizziness, fainting, or inability to stay awake

›Persistent vomiting or inability to keep fluids down

›Chest pain, shortness of breath, or leg swelling (clot risk)

›Sudden scrotal pain or swelling

›Worsening confusion or difficulty speaking

›Follow-up instructions

›Book a fasting morning blood test (drawn between 7-10 AM) within 1-2 weeks

›Do not eat before the blood test; blood drawn ideally after a full night's sleep

›Follow up with your family doctor or endocrinologist within 2 weeks

›Medications and lifestyle

›Do not start testosterone replacement without specialist guidance

›If you take opioid pain medications, speak to your doctor about their effects on testosterone

›Weight loss of even 5-10% of body weight can significantly improve testosterone levels

›Alcohol consumption can further lower testosterone — limit intake

›If you have been prescribed testosterone therapy

›Apply gel to clean dry skin on shoulders or upper arms; avoid genital skin

›Wash hands thoroughly after applying; prevent skin-to-skin transfer to others

›Do not use testosterone if you are trying to father a child — it prevents sperm production

›Blood tests including blood count and PSA will be repeated in 3 months

12References/r27

Guidelines and key sources

›Primary clinical practice guidelines

›Bhasin S et al. Testosterone Therapy in Men With Hypogonadism: Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018

›Primary evidence base for TRT initiation, monitoring, and contraindications

›De Silva NL et al. Male Hypogonadism: Pathogenesis, Diagnosis, and Management. Lancet Diabetes Endocrinol. 2024

›Comprehensive review of HPG axis failure classification

›Fleseriu M et al. Hypopituitarism. Lancet. 2024

›Panhypopituitarism diagnosis and hormone replacement

›Fleseriu M et al. Hormonal Replacement in Hypopituitarism in Adults: Endocrine Society Clinical Practice Guideline. JCEM. 2016

›Glucocorticoid and hormone replacement protocols

›Iglesias P. Pituitary Apoplexy: An Updated Review. J Clin Med. 2024

›Management of acute pituitary hemorrhage/infarction

›Biagetti B et al. Update on the Management of Pituitary Apoplexy. Eur J Endocrinol. 2026

›Updated surgical and conservative thresholds

›Fountas A, Van Uum S, Karavitaki N. Opioid-Induced Endocrinopathies. Lancet Diabetes Endocrinol. 2020

›Mechanism and prevalence of opioid HPG suppression

›Kanakis GA et al. EMAS Position Statement: Testosterone Replacement Therapy in Older Men. Maturitas. 2023

›Risk-benefit framework for TRT in men >=65

›Boeri L et al. Testosterone Therapy in Adult Males With Hypogonadism. Eur Urol. 2025

›Monitoring protocols and structured follow-up

›Bhasin S, Snyder PJ. Testosterone Treatment in Middle-Aged and Older Men. NEJM. 2025

›TRAVERSE trial data on cardiovascular safety

›Lee H et al. Testosterone Replacement in Men With Sexual Dysfunction. Cochrane Database Syst Rev. 2024

›Efficacy of TRT for erectile and sexual function

›Basaria S. Male Hypogonadism. Lancet. 2014

›Foundational epidemiology and classification

›Husebye ES et al. Adrenal Insufficiency. Lancet. 2021

›Adrenal crisis diagnosis and management

Learn More: Hypogonadism (Acute Presentation)→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.